Edward Sturchio
Consigliere Generale presso IMMATICS N.V.
Patrimonio netto: 1 M $ in data 30/04/2024
Provenienza dei contatti di primo grado di Edward Sturchio
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 23 | |
| Subsidiary | Medical Specialties | 17 | |
| Public Company | Pharmaceuticals: Major | 3 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Edward Sturchio tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Pharmaceuticals: Major | Chairman Director/Board Member Chief Executive Officer Founder Director of Finance/CFO Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX. | Biotechnology | Chairman Director/Board Member Director/Board Member Chief Executive Officer Founder Director/Board Member Director/Board Member Founder Chief Tech/Sci/R&D Officer | |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
dievini Hopp BioTech holding GmbH & Co. KG
 dievini Hopp BioTech holding GmbH & Co. KG Investment ManagersFinance dievini Hopp BioTech holding GmbH & Co. KG operates as a private investment and consulting firm. It invests in companies related to the life and health sciences. It focuses with companies that diagnoses and provides therapy in the fields of oncology, neurology, infectious diseases, cell therapy and drug delivery systems. The company is headquartered in Walldorf, Germany. | Investment Managers | Private Equity Investor Founder Chief Executive Officer | |
Molecular Health GmbH
 Molecular Health GmbH Miscellaneous Commercial ServicesCommercial Services Part of Posbelduf Biotech AG, Molecular Health GmbH is a German management consulting company. The company is based in Heidelberg, Germany. The company was founded in 2004 by Friedrich von Bohlen und Halbach. Friedrich von Bohlen und Halbach has been the CEO since 2004. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Director/Board Member | |
| AC IMMUNE SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Molecular Health, Inc.
 Molecular Health, Inc. Packaged SoftwareTechnology Services Molecular Health, Inc. operates as a cloud-based healthcare decision support technology to enable evidence-based treatment decisions. The company was founded in 2004 and is headquartered in Boston, MA. | Packaged Software | Chairman Director/Board Member Director/Board Member | |
| Eberhard Karls Universität Tübingen | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| dievini Verwaltungs GmbH | Chief Executive Officer Chief Executive Officer Chief Executive Officer | ||
| HEIDELBERG PHARMA AG | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| 2INVEST AG | Financial Conglomerates | Director/Board Member Director/Board Member | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Febit, Inc. | Director/Board Member Chairman | ||
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| IMMUNOCORE HOLDINGS PLC | Biotechnology | Chief Executive Officer Director/Board Member | |
Apogenix AG
 Apogenix AG BiotechnologyHealth Technology Apogenix AG develops immuno-oncology therapeutics for the treatment of cancer and malignant diseases. It offers protein-based therapeutics, including APG101, a human soluble fusion protein combining the extracellular domain of the CD95-receptor and the Fc part blocking CD95L-mediated signaling pathways; and IL-4 blocker that prevents over expression of anti-apoptotic proteins cells. The firm offers its drugs for malignant and inflammatory diseases. The company was founded by Peter Heinrich Krammer and Henning Walczak in 2005 and is headquartered in Heidelberg, Germany. | Biotechnology | Chairman Director/Board Member | |
Novaliq GmbH
 Novaliq GmbH Medical SpecialtiesHealth Technology Novaliq GmbH develops and markets drug delivery systems. The firm specializes in the development of novel pharmaceutical formulations based on semifluorinated alkanes . It product pipeline encompasses the NovaTears, CyckAol, and I-Let Protect technologies. The company was founded in 2004 and is headquartered in Heidelberg, Germany. | Medical Specialties | Chairman Director/Board Member | |
febit holding GmbH
 febit holding GmbH Medical/Nursing ServicesHealth Services febit holding GmbH engages in the design and development of technologies used for DNA analysis. It specializes in technologies with applications in genomic research, RNA expression profiling, and other diagnostic and molecular biology fields. The company was founded by Markus Beier, Ramon Gueimil, Peer F. Staehler, Matthias Scheffler, and Cord F. Stähler in 2005 and is headquartered in Heidelberg, Germany. | Medical/Nursing Services | Director/Board Member Chairman | |
Lantheus Medical Imaging, Inc.
 Lantheus Medical Imaging, Inc. Medical SpecialtiesHealth Technology Lantheus Medical Imaging, Inc. engages in the manufacture, marketing, sale, and distribution of medical imaging products. It provides diagnostic imaging and nuclear medicine products that assist clinicians with the detection of disease, primarily cardiovascular. Its product protfolio includes DEFINITY, TechneLite, Xenon, AZEDRA, Cardiolite, and NEUROLITE. The company was founded in 1956 and is headquartered in North Billerica, MA. | Medical Specialties | Director/Board Member Director/Board Member | |
| CUREVAC N.V. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Doctorate Degree | |
| Georgetown University | College/University | Undergraduate Degree Undergraduate Degree | |
| PROGENICS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| University of Michigan | College/University | Undergraduate Degree Graduate Degree | |
| LANTHEUS HOLDINGS, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
Advanced Accelerator Applications (UK & Ireland) Ltd.
 Advanced Accelerator Applications (UK & Ireland) Ltd. Medical SpecialtiesHealth Technology Imaging Equipment Ltd. distributes medical technologies. The firm offers PET and nuclear medical, imaging equipment, radiotherapy products, diagnostic imaging, radiation safety quality assurance, medical phantoms, ultrasound quality assurance products, molecular imaging, radiology tables, and bone densitometry products for the purpose of diagnosing osteoporosis. The company was founded in 2001 and is headquartered in Somerset, the United Kingdom. | Medical Specialties | Director/Board Member Director/Board Member | |
| NPS PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer General Counsel | |
PROMETHERA Biosciences SA
 PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| INFLARX N.V. | Biotechnology | Director of Finance/CFO Corporate Officer/Principal | |
Median Technologies, Inc.
 Median Technologies, Inc. Medical/Nursing ServicesHealth Services Part of MEDIAN Technologies SA, Median Technologies, Inc. provides medical imaging services. The company is based in Burlington, MA. The CEO of the company is Fredrik Bjjorn Brag. | Medical/Nursing Services | Director/Board Member | |
| University of Regensburg | College/University | Undergraduate Degree | |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom. | Biotechnology | Director/Board Member | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal | |
| FIVE PRIME THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| Max Planck Institute of Neurobiology | College/University | Doctorate Degree | |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology iOmx Therapeutics AG develops immunotherapy treatments for cancer patients. It specializes in immuno oncology, drug development and cancer therapy. The company was founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016 and is headquartered in Munich, Germany. | Biotechnology | Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Investor Relations Contact | |
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Chairman | |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Chief Executive Officer | |
| European Organisation for Research & Treatment of Cancer | Corporate Officer/Principal | ||
| The Indiana University School of Medicine | College/University | Corporate Officer/Principal |
Statistiche
Distribuzione geografica
| Germania | 25 |
| Stati Uniti | 19 |
| Regno Unito | 5 |
| Svizzera | 3 |
| Belgio | 3 |
Settori
| Health Technology | 32 |
| Consumer Services | 8 |
| Commercial Services | 4 |
| Health Services | 4 |
| Finance | 3 |
Posizioni
| Director/Board Member | 224 |
| Corporate Officer/Principal | 90 |
| Chairman | 76 |
| Independent Dir/Board Member | 67 |
| Chief Executive Officer | 56 |
Contatti più connessi
| Insiders | |
|---|---|
| Christof Hettich | 40 |
| Kapil Dhingra | 39 |
| Claudio Costamagna | 38 |
| Friedrich von Bohlen und Halbach | 36 |
| Eliot Forster | 35 |
| Francois Nader | 28 |
| Peter Chambré | 23 |
| Mathias Hothum | 19 |
| Adam Stone | 18 |
| Michael Atieh | 16 |
| Carsten Reinhardt | 16 |
| Arnd Christ | 15 |
| Steven Gannon | 14 |
| Susanne Antonie Schaffert | 13 |
| Heather Mason | 13 |
- Borsa valori
- Insiders
- Edward Sturchio
- Connessioni Società